BPMC (Blueprint Medicines) - Purchased 240 shares at $31.19

DEC makes its first investment with a purchase of 240 shares of BPMC at $31.19. Additional shares may be added on short term weakness in share price.

Blueprint specializes in developing drugs that target specific, genetically altered enzymes that drive malignancy in cancer cells. By inhibiting the enzyme only in the cancer cells and not in the rest of the body, the company should be able to achieve inhibition of cancer activity with greater potency and less toxicity than what is normally seen with existing anti cancer drugs. The company plans to initiate clinical trials for two lead drugs this year, and has published very promising preclinical data supporting the ability of the drugs to shut down cancer growth in mice.